Lack of cyclic AMP-specific phosphodiesterase 4 activation during naloxone-precipitated morphine withdrawal in rats

Neuroscience Letters

Volumn 404, Issue 1-2, 2006, Pages 107-111

  Kimura, Megumi ^a   Tokumura, Miwa ^a   Itoh, Tetsuji ^a   Inoue, Osamu ^b   Abe, Kohji ^a,b  

^a SHIONOGI AND CO LTD   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclic AMP; Cyclic AMP specific phosphodiesterase 4; Morphine withdrawal

Indexed keywords

MORPHINE; NALOXONE; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; JUMPING; MALE; MORPHINE ADDICTION; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROVOCATION TEST; RAT; WITHDRAWAL SYNDROME;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BRAIN; CYCLIC AMP; ENZYME ACTIVATION; MALE; MORPHINE; NALOXONE; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33745887223     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.05.014     Document Type: Article

References (21)

1. Adams J.U., and Holtzman S.G. Pharmacologic characterization of the sensitization to the rate-decreasing effects of naltrexone induced by acute opioid pretreatment in rats. J. Pharmacol. Exp. Ther. 253 (1990) 483-489
2. Bauer A.C., and Schwabe U. An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn-Schmiedebergs Arch. Pharmacol. 311 (1980) 193-198
3. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 48 (1991) 1991-2003
4. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63 (1999) 1-38
5. Duman R.S., Tallman J.F., and Nestler E.J. Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J. Pharmacol. Exp. Ther. 246 (1988) 1033-1039
6. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 69 (2001) 249-315
7. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. Adv. Pharmacol. 44 (1998) 225-342
8. Itoh A., Noda Y., Mamiya T., Hasegawa T., and Nabeshima T. A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine. Methods Find. Exp. Clin. Pharmacol. 20 (1998) 619-625
9. Jacobitz S., Mclaughlin M.M., Livi G.P., Burman M., and Torphy T.J. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 50 (1996) 891-899
10. Kaplan G.B., Sethi R.K., Mcclelland E.G., and Lette-Morris K.A. Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate-dependent and opiate withdrawing mice. Brain Res. 788 (1998) 104-110
11. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 21 (1997) 91-104
12. Mamiya T., Noda Y., Ren X., Hamdy M., Furukawa S., Kameyama T., Yamada K., and Nabeshima T. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor. Br. J. Pharmacol. 132 (2001) 1111-1117
13. Manganiello V. Short-term regulation of PDE4 activity. Br. J. Pharmacol. 136 (2002) 339-340
14. Mehats C., Andersen C.B., Filopanti M., Jin S.L., and Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocr. Metab. 13 (2002) 29-35
15. Nestler E.J., and Aghajanlan G.K. Molecular and cellular basis of addiction. Science 278 (1997) 58-63
16. Ohsawa F., Yamauchi M., Nagaso H., Murakami S., Baba J., and Sawa A. Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Jpn. J. Pharmacol. 77 (1998) 147-154
17. 3H]rolipram binding autoradiography: comparison with monkey and rat brain. J. Chem. Neuroanat. 20 (2000) 349-374
18. Schulteis G., Heyser C.J., and Koob G.F. Opiate withdrawal signs precipitated by naloxone following a single exposure to morphine: potentiation with a second morphine exposure. Psychopharmacology 129 (1997) 56-65
19. 3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1. Neurosci. Lett. 175 (1994) 89-91
20. 3H]rolipram binding in the rat brain. Biol. Pharm. Bull. 19 (1996) 300-302
21. Wiley J.N., and Downs D.A. Naloxone-precipitated jumping in mice pretreated with acute injections of opioids. Life Sci. 25 (1979) 797-802